Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone

BackgroundSodium-glucose co-transporter-2 inhibitors (SGLT2i) have cardiovascular (CV) benefits, particularly in reducing the risk of heart failure (HF). Pioglitazone (Pio) has shown potential in decreasing the risks of recurrent stroke, non-fatal myocardial infarction (MI), and all-cause mortality...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yan-Rong Li, Chih-Ching Wang, Chi-Hung Liu, Chieh-Li Yen, Victor Chien-Chia Wu, Evelyn Jou-Chen Huang, Ching-Yu Lee, Ching-Chung Hsiao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-08-01
coleção:	Frontiers in Endocrinology
Assuntos:	type 2 diabetes mellitus sodium-glucose co-transporter-2 inhibitors (SGLT2i) pioglitazone cardiovascular outcomes heart failure
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1420485/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!